{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:55:07Z","timestamp":1779206107288,"version":"3.51.4"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Statins are considered as the first line drugs for the treatment of hyperlipidemia. Despite proven efficacy of rosuvastatin, inter-individual variations in plasma rosuvastatin levels have been documented in various studies which causes variable response to statin tolerance. This study aims to evaluate the possible association of ABCG2 421 G\u2009&gt;\u2009T (rs2231142) polymorphism with inter-individual variations in plasma rosuvastatin levels which potentially increases the rosuvastatin related adverse effects. This quasi experimental study was carried out from June 2022 till December 2023 in two tertiary care hospitals of Pakistan. Hyperlipidemic patients with low density lipoprotein more than 130\u2009mg\/dl were enrolled through non-probability purposive sampling. All the enrolled patients were treated with rosuvastatin 10\u2009mg once daily for 12 weeks. Fasting lipid profile, serum creatine phosphokinase, liver and renal function tests were measured at the start of study and after 12 weeks of intervention with rosuvastatin. Blood samples were also collected for genotyping and determination of plasma rosuvastatin levels. Frequency of ABCG2 421 G\u2009&gt;\u2009T polymorphism for wild type GG, heterozygous mutant GT and homozygous mutant TT genotypes were 54.5, 36.2 and 9.3% respectively. Minor allele frequency was 0.27. Patients with TT and GT genotypes have significantly raised plasma levels of rosuvastatin with mean value of 30.23\u2009\u00b1\u20094.8\u2009ng\/mL and 22.35\u2009\u00b1\u20095.1\u2009ng\/mL respectively as compared to wild GG genotypes 13.95\u2009\u00b1\u20098.9\u2009ng\/mL (\n                    <jats:italic>\n                      <jats:italic>p<\/jats:italic>\n                    <\/jats:italic>\n                    =&lt;0.001). Frequency of myopathy, hepatotoxicity and nephrotoxicity in study population was 5.3, 3.2 and 4.8% respectively. All the genetic models including co-dominant model GT (OR= 5.45, 95% CI: 3.09\u20139.62,\n                    <jats:italic>\n                      <jats:italic>p<\/jats:italic>\n                    <\/jats:italic>\n                    =\u2009&lt;\u20090.0001), TT (OR= 88.51, 95% CI: 24.84\u2013315.44), dominant model (OR= 8.45, 95% CI: 4.91\u201314.52,\n                    <jats:italic>\n                      <jats:italic>p<\/jats:italic>\n                    <\/jats:italic>\n                    =\u2009&lt;\u20090.0001), recessive model (OR=37.29, 95%CI 11.06\u2013125.78, p\u2009&lt;\u20090.001), over-dominant model, (OR= 2.26, 95% CI: 1.42\u20133.60,\n                    <jats:italic>\n                      <jats:italic>p<\/jats:italic>\n                    <\/jats:italic>\n                    =\u2009&lt;\u20090.0001) showed significant association with rosuvastatin adverse effects. It is inferred that patients having T variant allele is associated with higher plasma rosuvastatin concentration and increased the risk of development of adverse effects compared with G allele carriers. It is therefore suggested that genetic profiling may be done for dose tailoring to minimize the statin intolerance.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0334600","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:36:16Z","timestamp":1760722576000},"page":"e0334600","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of ABCG2 421G&gt;T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-920X","authenticated-orcid":true,"given":"Mahjabeen","family":"Sharif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulsoom","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudassar","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsan Maqbool","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilshad Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja Kamran","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3763-5303","authenticated-orcid":true,"given":"Muhammad Bilal","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"1","key":"pone.0334600.ref001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12944-022-01747-2","article-title":"Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002-2012)","volume":"21","author":"M Georgoulis","year":"2022","journal-title":"Lipids Health Dis"},{"key":"pone.0334600.ref002","first-page":"010254","article-title":"Lipid-lowering efficacy of rosuvastatin","volume":"11","author":"SP Adams","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"pone.0334600.ref003","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40264-024-01413-9","article-title":"The Role of Mitochondria in Statin-Induced Myopathy","volume":"47","author":"G Bell","year":"2024","journal-title":"Drug Saf"},{"issue":"5","key":"pone.0334600.ref004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/biomedicines12050987","article-title":"Drug-Induced Myopathies: A Comprehensive Review and Update","volume":"12","author":"S Miernik","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"pone.0334600.ref005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/genes16030248","article-title":"The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles","volume":"16","author":"R Morris","year":"2025","journal-title":"Genes (Basel)"},{"issue":"9","key":"pone.0334600.ref006","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15337","article-title":"Statin-associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies","volume":"27","author":"M Shah","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"17","key":"pone.0334600.ref007","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"M Ruscica","year":"2022","journal-title":"Cardiovascular Research"},{"issue":"10","key":"pone.0334600.ref008","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11095-021-03109-6","article-title":"Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions","volume":"38","author":"N Hanke","year":"2021","journal-title":"Pharm Res"},{"issue":"4","key":"pone.0334600.ref009","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425255.2021.1876661","article-title":"ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?","volume":"17","author":"H Bruckmueller","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"pone.0334600.ref010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/17425255.2024.2362184","article-title":"Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol","volume":"20","author":"A Kasten","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"pone.0334600.ref011","doi-asserted-by":"crossref","first-page":"010502","DOI":"10.11613\/BM.2021.010502","article-title":"Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies","volume":"31","author":"CC Serdar","year":"2021","journal-title":"Biochem Med (Zagreb)"},{"issue":"10","key":"pone.0334600.ref012","article-title":"Comparison of DNA extraction methods for COVID-19 host genetics studies","volume":"18","author":"RC da Silva","year":"2023","journal-title":"PLoS One"},{"issue":"7","key":"pone.0334600.ref013","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00228-020-02882-4","article-title":"Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin","volume":"76","author":"D Zhang","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pone.0334600.ref014","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13071-023-05754-9","article-title":"A duplex tetra-primer ARMS-PCR assay to discriminate three species of the Schistosoma haematobium group: Schistosoma curassoni, S. bovis, S. haematobium and their hybrids","volume":"16","author":"M Blin","year":"2023","journal-title":"Parasit Vectors"},{"key":"pone.0334600.ref015","article-title":"The Effects of Three ABCG2 Polymorphisms on Outcome of Central Nervous System Relapses in Iranian Children With Acute Lymphoblastic Leukemia Receiving High Dose Methotrexate","author":"R Karamikhah","year":"2021","journal-title":"ACTA"},{"issue":"1","key":"pone.0334600.ref016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bcp.15485","article-title":"A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics","volume":"89","author":"M Lehtisalo","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pone.0334600.ref017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03208-9","article-title":"Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol","volume":"11","author":"S Aslam","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0334600.ref018","doi-asserted-by":"crossref","first-page":"752960","DOI":"10.3389\/fphar.2021.752960","article-title":"Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers","volume":"12","author":"AMR Silveira","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0334600.ref019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12881-020-0987-4","article-title":"ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population","volume":"21","author":"J Liu","year":"2020","journal-title":"BMC Med Genet"},{"issue":"19","key":"pone.0334600.ref020","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.3390\/app131910709","article-title":"Epicardial Adipose Tissue Changes during Statin Administration in Relation to the Body Mass Index: A Longitudinal Cardiac CT Study","volume":"13","author":"P Toia","year":"2023","journal-title":"Applied Sciences"},{"issue":"10","key":"pone.0334600.ref021","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/genes11101144","article-title":"Comprehensive Analysis of ABCG2 Genetic Variation in the Polish Population and Its Inter-Population Comparison","volume":"11","author":"M S\u0142omka","year":"2020","journal-title":"Genes (Basel)"},{"issue":"7","key":"pone.0334600.ref022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FPC.0000000000000504","article-title":"Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants","volume":"33","author":"KI L\u00f6nnberg","year":"2023","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"pone.0334600.ref023","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms","volume":"111","author":"RM Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0334600.ref024","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12872-024-03821-2","article-title":"Impacts of ABCG2 loss of function variant (p. Gln141Lys, c.421 C > A, rs2231142) on lipid levels and statin efficiency: a systematic review and meta-analysis","volume":"24","author":"Y Liu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"21","key":"pone.0334600.ref025","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy","volume":"22","author":"P Vinci","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"pone.0334600.ref026","first-page":"89","article-title":"Statin-related Muscle Toxicity: An Evidence-based Review","volume":"18","author":"MS Jeeyavudeen","year":"2022","journal-title":"European Endocrinology"},{"issue":"2","key":"pone.0334600.ref027","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00228-021-03233-7","article-title":"Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study","volume":"78","author":"I Mer\u0107ep","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0334600.ref028","first-page":"103304","article-title":"Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics","volume":"74","author":"W Abed","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"pone.0334600.ref029","first-page":"9","article-title":"Frequency of myalgias in patients taking statins treatment of dyslipidemia","volume":"19","author":"Z Jahanzeb","year":"2021","journal-title":"Ophthalmology Update"},{"issue":"10","key":"pone.0334600.ref030","first-page":"4708","article-title":"The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study","volume":"27","author":"M Zakria","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"pone.0334600.ref031","article-title":"Statins and Abnormal Liver Function Tests: Is There a Correlation?","volume":"12","author":"J Ashraf","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"pone.0334600.ref032","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury","volume":"116","author":"Practice Parameters Committee of the American College of Gastroenterology","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"pone.0334600.ref033","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101066","article-title":"The rise of the statins and the burdening inefficiencies in liver monitoring","volume":"4","author":"H Al-Gailani","year":"2020","journal-title":"BJGP Open"},{"issue":"2","key":"pone.0334600.ref034","article-title":"Comparison of the Efficacy of Rosuvastatin 5\u2009mg and 10\u2009mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia","volume":"14","author":"M Aleem","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"pone.0334600.ref035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40264-022-01202-2","article-title":"Kidney Damage and Stress Biomarkers for Early Identification of Drug-Induced Kidney Injury: A Systematic Review","volume":"45","author":"RJ Desai","year":"2022","journal-title":"Drug Saf"},{"issue":"2","key":"pone.0334600.ref036","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin Toxicity","volume":"124","author":"NC Ward","year":"2019","journal-title":"Circ Res"},{"issue":"3","key":"pone.0334600.ref037","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2016.08.037","article-title":"Renal Tubular Toxicity Associated With Rosuvastatin Therapy","volume":"69","author":"FL Ward","year":"2017","journal-title":"American Journal of Kidney Diseases"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:36:24Z","timestamp":1760722584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334600"}},"subtitle":[],"editor":[{"given":"James M","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334600","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}